Malignant bowel obstruction in advanced ovarian cancer

Emma Dean; Leila Khoja; Andrew Clamp; Gordon C Jayson; Dilly Goonetilleke; Alicia M Conway; Jurjees Hasan

doi:10.2217/fon-2016-0431

Malignant bowel obstruction in advanced ovarian cancer

Emma Dean, Leila Khoja, Andrew Clamp, Gordon C Jayson, Dilly Goonetilleke, Alicia M Conway, Jurjees Hasan

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.

Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.

Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).

Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.

Original language	English
Pages (from-to)	513-521
Number of pages	9
Journal	Future Oncology
Volume	13
Issue number	6
Early online date	18 Jan 2017
DOIs	https://doi.org/10.2217/fon-2016-0431
Publication status	Published - 1 Jun 2017

Keywords

bowel obstruction
Manchester Bowel Obstruction Score
ovarian cancer
prognostic score

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2016-0431

Cite this

@article{d1027f3b0a6a41a597283aca0afdf2f9,

title = "Malignant bowel obstruction in advanced ovarian cancer",

abstract = "Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.",

keywords = "bowel obstruction, Manchester Bowel Obstruction Score, ovarian cancer, prognostic score",

author = "Emma Dean and Leila Khoja and Andrew Clamp and Jayson, {Gordon C} and Dilly Goonetilleke and Conway, {Alicia M} and Jurjees Hasan",

year = "2017",

month = jun,

day = "1",

doi = "10.2217/fon-2016-0431",

language = "English",

volume = "13",

pages = "513--521",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine ",

number = "6",

}

TY - JOUR

T1 - Malignant bowel obstruction in advanced ovarian cancer

AU - Dean, Emma

AU - Khoja, Leila

AU - Clamp, Andrew

AU - Jayson, Gordon C

AU - Goonetilleke, Dilly

AU - Conway, Alicia M

AU - Hasan, Jurjees

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.

AB - Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.

KW - bowel obstruction

KW - Manchester Bowel Obstruction Score

KW - ovarian cancer

KW - prognostic score

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85012154604&partnerID=MN8TOARS

U2 - 10.2217/fon-2016-0431

DO - 10.2217/fon-2016-0431

M3 - Article

C2 - 28095701

SN - 1479-6694

VL - 13

SP - 513

EP - 521

JO - Future Oncology

JF - Future Oncology

IS - 6

ER -

Malignant bowel obstruction in advanced ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this